Table 5.
Manual Quantitative HER2/neu IHC Score
|
Total | Positive Rate (HER2/neu IHC 3+), % | ||||
---|---|---|---|---|---|---|
0 | 1+ | 2+ | 3+ | |||
Stagea | ||||||
IA | 4 | 3 | 0 | 2 | 9 | 22 |
IB | 3 | 1 | 0 | 0 | 4 | 0 |
IIA | 1 | 0 | 0 | 0 | 1 | 0 |
IIB | 10 | 0 | 0 | 0 | 10 | 0 |
IIIA | 5 | 1 | 0 | 0 | 6 | 0 |
IIIB | 0 | 1 | 0 | 1 | 2 | 50 |
IIIC | … | … | … | … | 0 | … |
IV | … | … | … | … | 0 | … |
Total | 23 | 6 | 0 | 3 | 32 | |
Grade 1 | 4 | 1 | 0 | 1 | 6 | 17 |
Grade 2 | 6 | 3 | 0 | 2 | 11 | 18 |
Grade 3 | 13 | 2 | 0 | 0 | 15 | 0 |
Total | 23 | 6 | 0 | 3 | 32 | |
Overall cases with HER2/neu overexpression: 3/32 (9%) |
Abbreviations: HER2/neu, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
American Joint Committee on Cancer/International Union Against Cancer tumor-node-metastasis (AJCC/UICC TNM) classification, 7th edition.